| HOME >> MEDICINE >> TECHNOLOGY |
Table 39: Immunochemistry Market, India, Revenue ($m), 2003–2010 66
Table 40: Immunochemistry Market, India, Revenue ($m), 2010–2017 67
Table 41: Immunochemistry Market, Australia, Revenue ($m), 2003–2010 68
Table 42: Immunochemistry Market, Australia, Revenue ($m), 2010–2017 69
Table 43: Immunochemistry Market, Brazil, Revenue ($m), 2003–2010 70
Table 44: Immunochemistry Market, Brazil, Revenue ($m), 2010 – 2017 71
Table 45: Immunochemistry Market, Global, Company Shares by Revenues ($m), 2009 72
Table 46: Immunochemistry Portfolio, F. Hoffmann-La Roche Ltd., 2011 73
Table 47: Immunochemistry Pipeline Portfolio, F. Hoffmann-La Roche Ltd., 2011 74
Table 48: Immunochemistry Portfolio, Siemens Healthcare, 2011 77
Table 49: Immunochemistry Pipeline Portfolio, Siemens Healthcare, 2011 78
Table 50: Immunochemistry Portfolio, Abbott Laboratories, 2010 81
Table 51: Immunochemistry Pipeline Portfolio, Abbott Laboratories, 2010 81
Table 52: Immunochemistry Portfolio, Alere Inc., 2011 85
Table 53: Immunochemistry Pipeline Portfolio, Alere Inc., 2011 85
Table 54: PROGENSA PCA3 Assay , Product Status, 2011 88
Table 55: PROGENSA PCA3 Assay – Molecular Urine Tests for Prostate Cancer 88
Table 56: PROGENSA PCA3 Assay – Clinical Evaluation of the PROGENSA PCA3 Assay in Men With a Previous Negative Biopsy Result 89
Table 57: CertNDx Bladder Cancer Assay, Product Status, 2011 90
Table 58: CertNDx Bladder Cancer Assay – Phase III Study of Bladder Cancer Recurrence Surveillance 90
Table 59: CertNDx Bladder Cancer Assay – A Study On ADAM 12 Cleaving Extracellular Matrix Proteins and Correlate With Cancer Status and Stage 91
Table 60: ADVIA Centaur CP System – UE3 Assay, Product Status, 2011 92
Table 61:
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |